$CNTB News

Last published 1mo ago

1mo agoCNTBConnect Biopharma Conference Call - CONNECT BIOPHARMA HOLDINGS LTDEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to the Connect Biopharma conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-
1mo agoCNTBConnect Biopharma Conference Call - CONNECT BIOPHARMA HOLDINGS LTDEarnings Call TranscriptsGood day, ladies and gentlemen. Thank you for standing by. Welcome to the Connect Biopharma conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a que
1mo agoCNTBConnect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 InflammationGlobeNewswire– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to
2mo agoCNTBConnect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for
3mo agoCNTBConnect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway
4mo agoCNTBConnect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in AsthmaGlobeNewswire– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway
6mo agoCNTBConnect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceGlobeNewswireSAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the
6mo agoCNTBConnect Biopharma Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2
6mo agoCNTBConnect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim AnalysisGlobeNewswireSAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for
7mo agoCNTBConnect Biopharma Reports 2025 Full-Year Financial Results and Provides Business UpdateGlobeNewswire– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session
7mo agoCNTBCONNECT BIOPHARMA CONFERENCE CALL - CONNECT BIOPHARMA HOLDINGS LTDEarnings Call TranscriptsLadies and gentlemen, thank you for standing by and welcome to the Connect BioPharma conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question a
7mo agoCNTBConnect Biopharma Announces $20.2 Million Private Placement FinancingGlobeNewswireFunding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect
7mo agoCNTBRademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis StudyGlobeNewswire– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to
7mo agoCNTBConnect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPDGlobeNewswire– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in
8mo agoCNTBResults from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual MeetingGlobeNewswireSAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for
8mo agoCNTBConnect Biopharma to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewswireSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care
8mo agoCNTBConnect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireSAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care
8mo agoAMGN CNTB NKTR APGE+6Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsightPR NewswireRecently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis...
10mo agoCNTBConnect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026GlobeNewswire– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to
11mo agoCNTBConnect Biopharma to Present at the 8th Annual Evercore Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care
12mo agoCNTBConnect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademikibart for the treatment of
1y agoCNTBConnect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025GlobeNewswire– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest improvements observed in those with elevated baseline levels of key type 2 inflammatory markers –
1y agoCNTBConnect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025GlobeNewswireSAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for
1y agoCNTBConnect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on NasdaqGlobeNewswireSAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the
1y agoCNTBConnect Biopharma to Present at Two Upcoming Investor Conferences in SeptemberGlobeNewswireSAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the
1y agoCNTBConnect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program NationwideGlobeNewswireCompany and Former Cincinnati Bengals Running Back Known for the "Ickey Shuffle" Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE
1y agoCNTBConnect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the potential of
1y agoCNTBConnect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of DirectorsGlobeNewswire– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN
1y agoCNTBConnect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on NasdaqGlobeNewswireSAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the
1y agoCNTBConnect Biopharma to Participate in the BTIG Virtual Biotechnology ConferenceGlobeNewswireSAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care
1y agoCNTBConnect Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireSAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the
1y agoCNTBConnect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual CongressGlobeNewswire– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2
1y agoCNTBConnect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual CongressGlobeNewswireSAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and chronic
1y agoCNTBConnect Biopharma to Present at Two Upcoming Investor Conferences in JuneGlobeNewswireSAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and chronic
1y agoCNTBConnect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International ConferenceGlobeNewswire– Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing
1y agoCNTBConnect Biopharma Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireInitiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026
1y agoCNTBConnect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPDGlobeNewswire– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company),
1y agoCNTBConnect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in AsthmaGlobeNewswire– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE)
1y agoCNTBConnect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International ConferenceGlobeNewswire– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Advancing rapid clinical development plan for rademikibart; expect
1y agoCNTBConnect Biopharma Announces Positive Type C Meeting with the FDA for RademikibartGlobeNewswire– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO,
1y agoCNTBConnect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled AsthmaGlobeNewswire– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL)
1y agoCNTBConnect Biopharma Reports 2024 Full-Year Financial Results and Provides Business UpdateGlobeNewswireStrengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise Unveiled rapid
1y agoCNTBConnect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewswireSAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic
1y agoCNTBConnect Biopharma to Present at Two Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and
2y agoCNTBAttovia Therapeutics Appoints Chief Financial OfficerGlobeNewswireFREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and
2y agoCNTBConnect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024GlobeNewswireSAN DIEGO, CA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a U.S.-headquartered global clinical-stage biopharmaceutical company
2y agoCNTBConnect Biopharma Reports First Half 2024 Financial Results and Provides Business UpdateGlobeNewswireAnnounced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect's new management is currently evaluating the future clinical
2y agoCNTBConnect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics ForumGlobeNewswireSAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company
2y agoCNTBConnect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company
2y agoCNTB GRIConnect Biopharma Announces New Leadership and Chair of the Board of DirectorsGlobeNewswireIndustry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life